Trump Faces Poll Decline Amid Mixed Foreign Policy and Domestic Developments
President Trump's disapproval rating has reached its highest point of his second term, with rising gas prices linked to the Iran conflict cited as contributing factors. Separately, Trump announced a three-week extension of the Israel-Lebanon ceasefire, while also making unverified crowd-size claims comparing his 2019 rally to the 1963 March on Washington. The FDA also approved the first gene therapy for a rare form of deafness, developed by Regeneron Pharmaceuticals.
Progressive outlets are likely to highlight Trump's record-high disapproval ratings as a public referendum on his economic and foreign policy decisions, and to scrutinize his crowd-size claims about MLK's speech as factually unfounded and historically disrespectful.
Polling data shows Trump's disapproval at a second-term high, while his administration simultaneously announced a ceasefire extension in the Middle East and made crowd-size claims that are not supported by documented historical attendance estimates.
Conservative outlets are likely to credit Trump with brokering the Israel-Lebanon ceasefire extension as a foreign policy achievement, while framing poll fluctuations as temporary and media-driven rather than reflective of broad public sentiment.
Polling data shows Trump's disapproval at a second-term high, while his administration simultaneously announced a ceasefire extension in the Middle East and made crowd-size claims that are not supported by documented historical attendance estimates.
Trump's disapproval rating hit a second-term high as the FDA approved a gene therapy for deafness, a ceasefire extension was announced for Israel and Lebanon, and Trump made disputed claims about his 2019 rally attendance.